MiNK Therapeutics, Inc. (NASDAQ:INKT), a New York-based clinical-stage biopharmaceutical company, has announced that its investigational allogeneic invariant natural killer T (iNKT) cell therapy, agenT-797, will be presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting from May 11-15, 2026, in Boston, Massachusetts. The presentation, led by Dr. Terese C. Hammond, will focus on the therapy's ability to demonstrate adaptive immune modulation in treating cancer and immune-mediated diseases. AgenT-797 is designed to harness both innate and adaptive immunity, potentially improving patient outcomes in challenging cases such as solid tumors and severe pulmonary inflammation. MiNK Therapeutics is committed to developing next-generation immune therapies, emphasizing the importance of scalable manufacturing processes for accessible treatment solutions. Further details regarding the poster presentation will be provided by ASGCT in mid-April.